Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Protagonist Therapeutics Gets IBD Stock Rating Upgrade

On Tuesday, Protagonist Therapeutics got an upgrade for its IBD SmartSelect Composite Rating from 77 to 96.

The new score tells you the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The market's biggest winners often have a 95 or higher grade in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.

Protagonist Therapeutics has now climbed above a proper buy zone after clearing the 48.89 entry in a consolidation.

Discover The 3 Keys To Successful Stock Investing

One weak spot is the company's 61 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.

Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.

The company reported a 350% rise in earnings for Q4. Top line growth increased 184%, up from -100% in the prior quarter. That marks one quarter of increasing revenue gains.

Protagonist Therapeutics earns the No. 3 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR is the top-ranked stock within the group.

This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.